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medicines. 
Figure 1 The balance between young and olds. In 2000 about 10% (606 
million) of the global population was aged 60+; by 2050 this will be more 
than 21% (about 2 billion). 75% of people aged 60+ have one chronic 
condition but 50% have two or more chronic conditions (modified from 
Rhenu Bhuller –Global contract manufacturing Trends 2010).
Current manufacturing practices are facing a major global capacity 
shortage for the production of biotechnological drugs and there are 
fewer than two dozen facilities worldwide capable of large-scale 
biotech manufacturing. Furthermore, the capacity challenge is also 
expected to become more complex over the next decades. 
In the last years, research has revolutionized the use of valuable 
proteins for a variety of treatments and their production became 
possible since several genes can be efficiently expressed in many 
different biological systems.1 The expression systems so far available 
offer different advantages for the preparation of the recombinant 
proteins, in general, the optimal technical approach should guarantee 
the safety, the biological activity and the economic production. 
Molecular Farming, is a term indicating the technology for the 
production of high-value compounds in transgenic animals, and 
it is nowadays used to refer to the production of pharmaceutically 
important and commercially valuable proteins in plants.2
Plants have been serving as an extremely useful source for 
treatments and therapies. Thousands of plant species are historically 
used to deal with common diseases and most of the world population 
uses them to cure acute and chronic health problems. After a shift 
from wild collection to cultivation, advances in plant biotechnology 
were aimed to direct improvement and modification of specialized 
constituents of plants like carbohydrates, proteins, oils, fats and 
vitamins, over a long time.
The use of engineered plants as “bioreactors” for the production of 
high-value recombinant proteins for industrial and clinical applications 
has become a promising alternative tool to the conventional bio-
production systems, such as bacteria, yeast, and cultured insects and 
animal cells (Figure 2).3
Figure 2 Schematic illustration of expression of transgene in plants. Left 
panel: infiltration of Agrobacterium carrying the GFP transgene; right panel: 
visualization of transient expression of the fluorescent protein four days post 
infiltration examined under a UV lamp.4
What is the idea that withstands on “why to use 
plants?”
This novel system offers several advantages in terms of safety, 
quality, production and costs, as summarized in Table 1.
Plants are not infected by known human pathogens, such as 
bacteria, prions or viruses, decreasing the risks of pathogens cross-
contaminations and minimizing health dangers. Plants classically 
produce recombinant proteins with the correct folding activity and 
glycosylation4 which allow getting high quality recombinant proteins. 
Plants possess excellent biosynthetic capabilities, including the ability 
to use the solar energy (photosynthesis) and/or very simple media to 
support significant biomass and protein accumulation. Finally, they 
have a large potentiality for a low-cost production as well as easy 
distribution and storage due to a better stability of plant bio-products.
The use of plants as a production system of pharmacologically 
active compounds has been widely described in the last years and 
new evidences on the refining of this technique are ongoing. A few 
illustrative examples are here reported.
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The synergic collaboration between science and health policies led 
to a significant increase in life expectancy and, consequently, in world 
population (Figure 1). By contrast, fulfilling the needs of this growing 
population, in terms of quality and quantity of production of medical 
and pharmaceutical compounds, could become quite difficult. In 
addition, the outbreak of new infectious diseases, metabolic disorders, 
the increase of chronic diseases as well as the growing requirement of 
personalized therapies, will raise the demand for many protein-based 
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Table 1 Comparison of different expression platforms for the production of pharmaceutical5
Comparisons Transgenic plant Bacteria Yeast Transgenic animals
Safety High Low Unknown High
Contamination risks Low Endotoxins Low Virus, Prions, oncogenic DNA
Product quality High Low Medium High
Protein folding accuracy High Low Medium High
Glycosylation Minor differences None Incorrect Correct
Protein yield High Medium High High
Production scale Worldwide Limited Limited Limited
Scale-up capacity Very high High High Low
Overall cost Very low Low Medium High
In order to produce oligomer monoclonal antibodies, Huang et al.6 
developed a bean yellow dwarf virus (BeYDV) based single-vector 
DNA replicon system that permits simultaneous efficient high-level 
accumulation of two recombinant proteins in the same plant cells 
(tobacco leaves), allowing the production of 0.5 mg of antibody per 
gram leaf (fresh weight) within four days from vector infiltration. 
Mapp Biopharmaceutical Inc., using similar methodology, transiently 
expressed the humanized antibodies, MB-003 and ZMab, in tobacco 
leaves. MB-003 and ZMab were later combined and designated as 
ZMapp. The use of these antibodies as a pharmaceutical drug was 
found to efficiently cured 100% of Ebola infected primates (rhesus 
macaque).7 
On the other hands, in a recent years,8 Macuna pruriens (L.) 
(Fabaceae), in which the presence of a high amount of L-DOPA in 
seeds has been proved, attracted global attention for the possibility to 
produce this catecholamine precursor from natural resources. In fact, 
it has been reported that the dried endocarp powder obtained from M. 
pruriens bean may give some benefit in the treatment of Parkinson’s 
disease.9
More recently, another big challenge in term of plant-derived drugs 
utilization is a possible prevention of type-1 diabetes (T1D).10 T1D is 
a metabolic disease that leads the autoimmune destruction of insulin-
producing pancreatic beta cells. T1D is characterized by the presence 
of several autoantibodies in the serum of patients that are used as 
markers of beta cell autoimmunity. They include Islet Cell Antibodies 
(ICA, against cytoplasmic proteins in the beta cell), Glutamic Acid 
Decarboxylase (GAD-65) antibodies, Insulin Autoantibodies (IAA), 
and IA (protein tyrosine phosphatase) antibodies.11 
It has been proposed that, like a vaccine, oral administration of 
insulin may induce systemic immunological tolerance and thus 
prevent or delay the onset of T1D.12 Bertini et al.10 combined edible 
plant systems, namely spinach (Spinacia oleracea cultivar Industra) 
and red beet (Beta vulgaris cultivar Moulin Rouge), with the 
magnICON® expression system to develop a safe, cost-effective and 
environmentally sustainable platform for the large-scale production 
of GAD65. It is worth mentioning that the GAD65 autoantibodies 
are also involved in several neurological diseases such as in some of 
epileptic patients, Stiff Person Syndrome (SPS), cerebellar ataxia, and 
autoimmune encephalitis13 opening possible future application of such 
biotechnological platform.
In conclusion, plant-based protein/drug production for industrial 
and clinical applications, offers a promising technology that could 
be complementary or alternative to the conventional bio-production 
systems.
However, some burden in apply this useful technologies has to 
been considered, such as the lack of adequate international regulation 
that guarantee a good manufactural practice in term of genetically 
modified plants and that control the pharmaceuticals platforms 
involved in the production of these medicals compounds. 
It is desirable that many efforts will be employed in this way in 
order to guarantee to a majority part of world population the possibility 
to access these new medical compounds.
Acknowledgements
None.
Conflict of interest
The authors certify that they have no affiliations with or 
involvement in any organization or entity with any financial or non-
financial interest in the subject matter or materials discussed in this 
manuscript.
References
1. Daniell H, Streatfield SJ, Wycoff K. Medical molecular farming: production 
of antibodies, biopharmaceuticals, and edible vaccines in plants. Trends 
Plant Sci. 2001b;6(5):219–226.
2. Fischer R, Neil Emans N. Molecular farming of pharmaceutical proteins. 
Transgenic Res. 2000;9(4-5):279–299.
3. Sharma AK, Sharma MK. Plants as bioreactors: recent developments and 
emerging opportunities. Biotechnol Adv. 2009;27(6):811–832.
4. Yao J, Weng Y, Dickey A, et al. Plants as factories for human pharmaceuticals: 
applications and challenges. Int J Mol Sci. 2015;16(12):28549–28565. 
5. Spök A, Karner S. Plant molecular farming, opportunities and challenges. 
Office for official publications of the European Communities; Kopstal, 
Luxembourg. JRC Technical Report: EUR 23383 EN; 2008.
6. Huang Z, Phoolcharoen W, Lai H, et al. High-level rapid production of 
full-size monoclonal antibodies in plants by a single-vector DNA replicon 
system. Biotechnol Bioeng. 2010;106(1):9–17.
7. Qiu X, Wong G, Audet J, et al. Reversion of advanced Ebola virus disease in 
nonhuman primates with ZMapp. Nature. 2014;514(7520):47–53.
8. Singh SK, Yadav D, Lal R, et al. Inducing mutations through γ-irradiation in 
seeds of Mucuna pruriens for developing high L-DOPA-yielding genotypes. 
Int J Radiat Biol. 2017;93(4):426–432.
9. Lieu CA, Venkiteswaran K, Gilmour TP, et al. The Antiparkinsonian and 
Antidyskinetic mechanisms of Mucuna pruriens in the MPTP-treated 
nonhuman primate. Evid Based Complement Alternat Med. 2012;1–10.
Investigating the reliability and validity of an intimate partner violence screening tool for use in physical 
therapy practice
317
Copyright:
©2018 Walton et al.
Citation: Lombardi A, Maggi R. New insight of medical and molecular farming (MMF): the plants derived drugs. MOJ Anat & Physiol. 2018;5(5):315‒317. DOI: 
10.15406/mojap.2018.05.00216
10. Bertini E, Merlin M, Gecchele E, et al. Design of a Type-1 diabetes vaccine 
candidate using edible plants expressing a major autoantigen. Front Plant 
Sci. 2018;9:572.
11. Taplin CE, Barker JM. Autoantibodies in type 1 diabetes. Autoimmunity. 
2008;41(1):11–18.
12. Mowat A, Parker L, Beacock-Sharp H, et al. Oral tolerance: overview and 
historical perspectives. Ann NY Acad Sci. 2004;1029:1–8. 
13. Liimatainen S, Honnorat J, Pittock SJ, et al. GAD65 autoantibody 
characteristics in patients with co-occurring type 1 diabetes and epilepsy 
may help identify underlying epilepsy etiologies. Orphanet J Rare Dis. 
2018;13(1):55.
